- Home
- NUVL vs BOOT Comparison
NUVL vs BOOT Comparison
Compare NUVL & BOOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- BOOT
- Stock Information
- Founded
- NUVL 2017
- BOOT 1978
- Country
- NUVL United States
- BOOT United States
- Employees
- NUVL N/A
- BOOT N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- BOOT Clothing/Shoe/Accessory Stores
- Sector
- NUVL Health Care
- BOOT Consumer Discretionary
- Exchange
- NUVL Nasdaq
- BOOT Nasdaq
- Market Cap
- NUVL 5.8B
- BOOT 4.8B
- IPO Year
- NUVL 2021
- BOOT 2014
- Fundamental
- Price
- NUVL $77.76
- BOOT $171.03
- Analyst Decision
- NUVL Strong Buy
- BOOT Strong Buy
- Analyst Count
- NUVL 10
- BOOT 13
- Target Price
- NUVL $119.60
- BOOT $187.38
- AVG Volume (30 Days)
- NUVL 482.8K
- BOOT 747.3K
- Earning Date
- NUVL 08-11-2025
- BOOT 07-31-2025
- Dividend Yield
- NUVL N/A
- BOOT N/A
- EPS Growth
- NUVL N/A
- BOOT 29.02
- EPS
- NUVL N/A
- BOOT 6.36
- Revenue
- NUVL N/A
- BOOT $1,991,785,000.00
- Revenue This Year
- NUVL N/A
- BOOT $14.65
- Revenue Next Year
- NUVL N/A
- BOOT $12.92
- P/E Ratio
- NUVL N/A
- BOOT $26.87
- Revenue Growth
- NUVL N/A
- BOOT 16.70
- 52 Week Low
- NUVL $55.54
- BOOT $86.17
- 52 Week High
- NUVL $113.51
- BOOT $183.60
- Technical
- Relative Strength Index (RSI)
- NUVL 43.20
- BOOT 53.25
- Support Level
- NUVL $77.41
- BOOT $165.83
- Resistance Level
- NUVL $83.50
- BOOT $179.89
- Average True Range (ATR)
- NUVL 3.08
- BOOT 6.22
- MACD
- NUVL -0.75
- BOOT -0.49
- Stochastic Oscillator
- NUVL 14.84
- BOOT 41.23
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About BOOT Boot Barn Holdings Inc.
Boot Barn Holdings Inc operates specialty retail stores. The company sells western and work-related footwear, apparel, and accessories in the United States. It is a single operating segment, which includes net sales generated from its retail stores and e-commerce websites.